Eugene R. Schiff

48.3k total citations · 14 hit papers
372 papers, 28.9k citations indexed

About

Eugene R. Schiff is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Eugene R. Schiff has authored 372 papers receiving a total of 28.9k indexed citations (citations by other indexed papers that have themselves been cited), including 258 papers in Hepatology, 247 papers in Epidemiology and 55 papers in Surgery. Recurrent topics in Eugene R. Schiff's work include Hepatitis C virus research (181 papers), Liver Disease Diagnosis and Treatment (176 papers) and Hepatitis B Virus Studies (138 papers). Eugene R. Schiff is often cited by papers focused on Hepatitis C virus research (181 papers), Liver Disease Diagnosis and Treatment (176 papers) and Hepatitis B Virus Studies (138 papers). Eugene R. Schiff collaborates with scholars based in United States, Canada and Germany. Eugene R. Schiff's co-authors include Jules L. Dienstag, K. Rajender Reddy, Lennox J. Jeffers, Zachary Goodman, Janice K. Albrecht, Mitchell L. Shiffman, Stuart C. Gordon, Leon Schiff, John G. McHutchison and William M. Lee and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Eugene R. Schiff

362 papers receiving 27.7k citations

Hit Papers

Interferon Alfa-2b Alone or in Combination with... 1975 2026 1992 2009 1998 2002 1989 1999 2009 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C
    1998 2.8k citations John G. McHutchison, Stuart C. Gordon et al. profile →
  2. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection
    2002 1.7k citations Arie Regev, Lennox J. Jeffers et al. The American Journal of Gastroenterology profile →
  3. Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
    1989 1.4k citations Eugene R. Schiff, Jules L. Dienstag et al. profile →
  4. Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States
    1999 976 citations Jules L. Dienstag, Eugene R. Schiff et al. profile →
  5. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
    2009 889 citations John G. McHutchison, Mitchell L. Shiffman et al. profile →
  6. Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡
    2010 735 citations Eugene R. Schiff et al. Hepatology profile →
  7. Diseases of the liver
    1975 734 citations Eugene R. Schiff et al. profile →
  8. A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
    1995 680 citations Jules L. Dienstag, Eugene R. Schiff et al. profile →
  9. Long-term safety of lamivudine treatment in patients with chronic hepatitis B
    2003 596 citations Eugene R. Schiff, Jules L. Dienstag et al. Gastroenterology profile →
  10. Histological outcome during long-term lamivudine therapy
    2003 583 citations Jules L. Dienstag, Eugene R. Schiff et al. Gastroenterology profile →
  11. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial
    2010 515 citations Paul Y. Kwo, Eugene R. Schiff et al. profile →
  12. A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C
    2001 507 citations Mitchell L. Shiffman, Stuart C. Gordon et al. Hepatology profile →
  13. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence
    2016 331 citations Eugene R. Schiff et al. Hepatology profile →
  14. Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
    2021 261 citations Eugene R. Schiff et al. Hepatology profile →

Peers

Eugene R. Schiff
Michael Fried United States
Mitchell L. Shiffman United States
Antonio Craxı̀ Italy
Jules L. Dienstag United States
Thomas Berg Germany
Patrick Marcellin France
Thierry Poynard France
Daniel Dhumeaux France
Adrian M. Di Bisceglie United States
Stuart C. Gordon United States
Michael Fried United States
Eugene R. Schiff
Citations per year, relative to Eugene R. Schiff Eugene R. Schiff (= 1×) peers Michael Fried

Countries citing papers authored by Eugene R. Schiff

Since Specialization
Citations

This map shows the geographic impact of Eugene R. Schiff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eugene R. Schiff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eugene R. Schiff more than expected).

Fields of papers citing papers by Eugene R. Schiff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eugene R. Schiff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eugene R. Schiff. The network helps show where Eugene R. Schiff may publish in the future.

Co-authorship network of co-authors of Eugene R. Schiff

This figure shows the co-authorship network connecting the top 25 collaborators of Eugene R. Schiff. A scholar is included among the top collaborators of Eugene R. Schiff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eugene R. Schiff. Eugene R. Schiff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shiffman, Mitchell L., B. Freilich, Raj Vuppalanchi, et al.. (2019). Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease. Publisher.
2.
Younossi, Zobair M., Maria Stepanova, K. Rajender Reddy, et al.. (2018). Viral eradication is required for sustained improvement of patient‐reported outcomes in patients with hepatitis C. Liver International. 39(1). 54–59. 24 indexed citations
3.
Schiff, Eugene R., et al.. (2017). Hepatotoxicity by herbs: a practical review of a neglected disease.. PubMed. 36(4). 350–353.
4.
Kwo, Paul Y., Norman Gitlin, Ronald Nahass, et al.. (2016). Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. PMC. 5 indexed citations
5.
Schiff, Eugene R.. (2011). Diagnosing and treating hepatitis C virus infection.. PubMed. 17 Suppl 4. S108–15. 11 indexed citations
6.
Neff, Guy, et al.. (2011). The current economic burden of cirrhosis.. PubMed Central. 7(10). 661–71. 124 indexed citations
7.
Shiffman, Mitchell L., Paul J. Pockros, John G. McHutchison, et al.. (2010). Clinical trial: the efficacy and safety of oral PF‐03491390, a pancaspase inhibitor – a randomized placebo‐controlled study in patients with chronic hepatitis C. Alimentary Pharmacology & Therapeutics. 31(9). 969–978. 89 indexed citations
8.
Kardos, Keith, Eugene R. Schiff, Karam Mounzer, et al.. (2010). Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. Journal of Virological Methods. 172(1-2). 27–31. 87 indexed citations
9.
10.
Schiff, Eugene R., et al.. (2007). Acetaminophen safety and hepatotoxicity – where do we go from here?. Expert Opinion on Drug Safety. 6(4). 341–355. 87 indexed citations
11.
Molina, Enrique, et al.. (2005). Liver enzymes elevation after HAART in HIV‐HCV co‐infection. Journal of Viral Hepatitis. 12(4). 429–434. 15 indexed citations
12.
Pockros, Paul J., Mitchell L. Shiffman, Eugene R. Schiff, et al.. (2004). Epoetin Alfa Improves Quality of Life in Anemic Hcv–Infected Patients Receiving Combination Therapy. Hepatology. 40(6). 1450–1458. 116 indexed citations
13.
Méndez, Pedro, Kia Saeian, K. Rajender Reddy, et al.. (2001). Hepatitis C, cryoglobulinemia, and cutaneous vasculitis associated with unusual and serious manifestations. The American Journal of Gastroenterology. 96(8). 2489–2493. 6 indexed citations
14.
Strauss, Edna, Luiz Carlos da Costa Gayotto, Carlos Penha‐Gonçalves, et al.. (1999). Methionine, choline and betaine in oral solution for the treatment of alcoholic fatty liver: results of a multicenter randomized double-blind clinical trial. Hepatology. 30(4). 1 indexed citations
15.
Schiff, Eugene R., et al.. (1998). A Placebo Controlled Study of Lamivudine and Interferonalpha-2b in Patients with Chronic Hepatitis B Who PreviouslyFailed Interferon Therapy. Hepatology. 30 indexed citations
16.
17.
Chedid, Antonio, Samuel W. French, Timothy R. Morgan, et al.. (1993). Cell-mediated hepatic injury in alcoholic liver disease. Gastroenterology. 105(1). 254–266. 90 indexed citations
18.
Schiff, Eugene R.. (1993). Treatment algorithms for hepatitis B and C.. Gut. 34(2 Suppl). S148–S149. 10 indexed citations
19.
Pérez, Guido O., Jacques J. Bourgoignie, Helen Lee, et al.. (1990). HIV-1 and HTLV-I infection in renal transplant recipients.. PubMed. 3(1). 35–40. 4 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Fried Breakdown of academic impact, for papers by Mitchell L. Shiffman Breakdown of academic impact, for papers by Antonio Craxı̀ Breakdown of academic impact, for papers by Jules L. Dienstag Breakdown of academic impact, for papers by Thomas Berg Breakdown of academic impact, for papers by Patrick Marcellin Breakdown of academic impact, for papers by Thierry Poynard Breakdown of academic impact, for papers by Daniel Dhumeaux Breakdown of academic impact, for papers by Adrian M. Di Bisceglie Breakdown of academic impact, for papers by Stuart C. Gordon
Rankless by CCL
2026